Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| jRCT2031190073 | Other Identifier | Japan Registry of Clinical Trials (jRCT) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ohara Pharmaceutical Co., Ltd. | INDUSTRY |
| Japan Agency for Medical Research and Development | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
To evaluate the safety and pharmacokinetics of OP-724 and to determine the recommended dose of OP-724 against Primary Biliary Cholangitis patients.
This trial is a phase I trial aimed at examining the safety and tolerability of OP-724 in patients with primary biliary cholangitis and determining the recommended dose.
The subjects are patients diagnosed with primary biliary cholangitis and diagnosed as progress of fibrosis (Scheuer stage III or higher) as a result of liver tissue examination. As a dosing schedule, OP-724 is intravenously administered twice a week (4 hours) for 12 weeks. However, once 7 days prior to the first cycle of administration, a dose scheduled for the first cycle will be administered once by continuous intravenous administration for 4 hours, and safety and pharmacokinetics will be evaluated on the day of administration to the next day after administration. The dose level shall be 3 doses (140 mg/m2/4hrs, 280 mg/m2/4hrs [starting dose], 380 mg/m2/4hrs), of which 2 doses shall be registered for up to 6 patients each. The safety and pharmacokinetic data after OP-724 administration will be decided comprehensively to determine the recommended dose in the next phase.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OP-724 | Experimental | Dose: 140, 280, 380 mg/m2/4 hrs Administration method: [Level 1] 140 mg/m2/4 hours [Level 2] 280 mg/m2/4 hours (starting dose) [Level 3] 380 mg/m2/4 hours Continuous intravenous administration will be done for 4 hours twice a week. This procedure will be as one cycle and 12 cycles (12 weeks in total) will be conducted. On 7 days prior to the first cycle administration, a dose scheduled in the first cycle will be administered with continuous intravenous for 4 hours and the safety and pharmacokinetics on the day of administration to the next day after administration will be evaluated. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OP-724 | Drug | Twice a week for 4 hours continuous intravenous administration of OP-724 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence Rate of Serious Adverse Events (Side Effects) | Occurrence Rate of Serious Adverse Events (Side Effects) whose causal relationship with the investigational drug can not be denied. The data will be aggregated by each adverse event and cohort. | 28 days after the last administration of OP-724 |
| Measure | Description | Time Frame |
|---|---|---|
| Expression Ratio of Adverse Events | The data will be aggregated by each adverse event and cohort. | 28 days after the last administration of OP-724 |
| Percentage of Occurrence of Side Effects | The data will be aggregated by each side effect and cohort. |
| Measure | Description | Time Frame |
|---|---|---|
| Effectiveness: Serum Fibrosis Marker Level | Amount of change from baseline in serum fibrosis marker level at 12 weeks after administration. The data will be aggregated by each cohort. | 12 weeks after administration of OP-724 |
Inclusion Criteria:
(1) Of the confirmed patients * of primary biliary cholangitis, patients with progressive fibrosis (Scheuer classification stage III or higher) by liver biopsy.
* The diagnosis of primary biliary cholangitis (PBC) is based on the diagnostic criteria (2015) of "Study and research on refractory liver and biliary diseases". That is, one that corresponds to any one of the following is diagnosed as PBC.
(2) Patients with Performance Status 0 to 2.
(3) Patients aged 20 years or over and under 75 when acquiring informed consent.
(4) Regarding participation in this trial (including liver biopsy), patients who obtained informed consent by their own voluntary intention.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kiminori Kimura, MD | Tokyo Metropolitan Komagome Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tokyo Metropolitan Komagome Hospital | Bunkyō-Ku | Tokyo | 113-8677 | Japan | ||
| Kyushu University Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36442892 | Derived | Kimura M, Ogawa E, Harada K, Imamura J, Saio M, Ikura Y, Yatsuhashi H, Murata K, Miura K, Ieiri I, Tanaka A, Kimura K. Feasibility, safety and tolerability of the CREB-binding protein/beta-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study. BMJ Open Gastroenterol. 2022 Nov;9(1):e001001. doi: 10.1136/bmjgast-2022-001001. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008105 | Liver Cirrhosis, Biliary |
| ID | Term |
|---|---|
| D002780 | Cholestasis, Intrahepatic |
| D002779 | Cholestasis |
| D001649 | Bile Duct Diseases |
| D001660 | Biliary Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C492448 | ICG 001 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 28 days after the last administration of OP-724 |
| Drug Concentration (OP-724 and C-82) in Plasma | The data will be aggregated by each cohort. | A) Single administration part: pre-dose and post-dose at 0.5, 1, 2, 4, 5, 9 and 24 hours. / B) Continuous administration part: pre-dose and post-dose at 4 hours on Day 1 and 4 in Cycle 1, 5, 9 and 12 (each cycle is 7 days) |
| Parameters on Pharmacokinetics (OP-724 and C-82) : Maximum Plasma Concentration (Cmax) | The data will be aggregated by each cohort. | A) Single administration part: pre-dose and post-dose at 0.5, 1, 2, 4, 5, 9 and 24 hours. / B) Continuous administration part: pre-dose and post-dose at 4 hours on Day 1 and 4 in Cycle 1, 5, 9 and 12 (each cycle is 7 days) |
| Parameters on Pharmacokinetics (OP-724 and C-82) : Area Under the Curve (AUC 0-24h) | The data will be aggregated by each cohort. | A) Single administration part: pre-dose and post-dose at 0.5, 1, 2, 4, 5, 9 and 24 hours. / B) Continuous administration part: pre-dose and post-dose at 4 hours on Day 1 and 4 in Cycle 1, 5, 9 and 12 (each cycle is 7 days) |
| Liver Tissue Fibrotic Area Ratio by Liver Biopsy | Amount of change from baseline in liver tissue fibrotic area ratio by liver biopsy at 12 weeks after administration. The data will be aggregated by each cohort. | 12 weeks after administration of OP-724 |
| Liver Stiffness by Fibro Scan | Amount of change from baseline of liver stiffness by Fibro Scan at 12 weeks after administration. The data will be aggregated by each cohort. | 12 weeks after administration of OP-724 |
| Child-Pugh Score | Amount of change from baseline of Child-Pugh Score at 12 weeks after administration. Child Pugh score (scale range 5-15 points, the severity increases sequentially from 5 to 15 points) is obtained by adding the score for each parameter (hepatic encephalopathy, ascites, bilirubin, albumin, PT). Based on the total points score (Child-Pugh Score) of each diagnostic parameter shown above, the severity of the disease is classified into Grades A to C shown below. The data will be aggregated by each cohort and score.
| 12 weeks after administration of OP-724 |
| MELD Score | Amount of change from baseline in MELD score at 12 weeks after administration. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing the severity of chronic liver disease and uses the subject's values for total bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict survival. MELD is calculated according to the following formula: * MELD score = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43 The data will be aggregated by each cohort and score. | 12 weeks after administration of OP-724 |
| Modified Histological Activity Index (HAI) | Amount of change from baseline of modified Histological Activity Index (HAI) and classification of Nakanuma et al. by liver biopsy at 12 weeks after administration. The data will be aggregated by each cohort and index | 12 weeks after administration of OP-724 |
| Serum Alkaline Phosphatase (ALP) Level | Amount of change from baseline in serum ALP level at 12 weeks after administration. The data will be aggregated by each cohort and Child-Pugh score. | 12 weeks after administration of OP-724 |
| Serum Total Bilirubin Value | Amount of change from baseline in serum total bilirubin value at 12 weeks after administration. The data will be aggregated by each cohort and Child-Pugh score. | 12 weeks after administration of OP-724 |
| Enhanced Liver Fibrosis Panel (ELF) Score | Amount of change from baseline of ELF score at 12 weeks after administration. Observation items: hyaluronic acid, procollagen III peptide, TIMP-1 * ELF score = 2.278 + 0.851 ln (hyaluronic acid) + 0.75 ln (P3 NP) + ln (TIMP). The data will be aggregated by each cohort and score. | 12 weeks after administration of OP-724 |
| Fukuoka |
| 812-8582 |
| Japan |
| D004066 |
| Digestive System Diseases |
| D008107 | Liver Diseases |
| D008103 | Liver Cirrhosis |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |